238 related articles for article (PubMed ID: 19491285)
1. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.
Jarnagin WR; Schwartz LH; Gultekin DH; Gönen M; Haviland D; Shia J; D'Angelica M; Fong Y; DeMatteo R; Tse A; Blumgart LH; Kemeny N
Ann Oncol; 2009 Sep; 20(9):1589-1595. PubMed ID: 19491285
[TBL] [Abstract][Full Text] [Related]
2. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
Konstantinidis IT; Do RK; Gultekin DH; Gönen M; Schwartz LH; Fong Y; Allen PJ; D'Angelica MI; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Ann Surg Oncol; 2014 Aug; 21(8):2675-83. PubMed ID: 24664624
[TBL] [Abstract][Full Text] [Related]
3. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
Kemeny NE; Schwartz L; Gönen M; Yopp A; Gultekin D; D'Angelica MI; Fong Y; Haviland D; Gewirtz AN; Allen P; Jarnagin WR
Oncology; 2011; 80(3-4):153-9. PubMed ID: 21677464
[TBL] [Abstract][Full Text] [Related]
4. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
[TBL] [Abstract][Full Text] [Related]
5. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
Cercek A; D'Angelica M; Power D; Capanu M; Gewirtz A; Patel D; Allen P; Fong Y; DeMatteo RP; Jarnagin WR; Kemeny NE
Ann Surg Oncol; 2014 Feb; 21(2):479-86. PubMed ID: 24154839
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.
Kemeny N; Gonen M; Sullivan D; Schwartz L; Benedetti F; Saltz L; Stockman J; Fong Y; Jarnagin W; Bertino J; Tong W; Paty P
J Clin Oncol; 2001 May; 19(10):2687-95. PubMed ID: 11352961
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma.
Kemeny N; Eid A; Stockman J; Gonen M; Schwartz L; Tetzlaff E; Paty P
J Surg Oncol; 2005 Aug; 91(2):97-101. PubMed ID: 16028279
[TBL] [Abstract][Full Text] [Related]
9. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
Kemeny N; Jarnagin W; Gonen M; Stockman J; Blumgart L; Sperber D; Hummer A; Fong Y
J Clin Oncol; 2003 Sep; 21(17):3303-9. PubMed ID: 12947066
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.
Ben-Josef E; Normolle D; Ensminger WD; Walker S; Tatro D; Ten Haken RK; Knol J; Dawson LA; Pan C; Lawrence TS
J Clin Oncol; 2005 Dec; 23(34):8739-47. PubMed ID: 16314634
[TBL] [Abstract][Full Text] [Related]
14. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
House MG; Kemeny NE; Gönen M; Fong Y; Allen PJ; Paty PB; DeMatteo RP; Blumgart LH; Jarnagin WR; D'Angelica MI
Ann Surg; 2011 Dec; 254(6):851-6. PubMed ID: 21975318
[TBL] [Abstract][Full Text] [Related]
15. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma.
Kemeny N; Conti JA; Cohen A; Campana P; Huang Y; Shi WJ; Botet J; Pulliam S; Bertino JR
J Clin Oncol; 1994 Nov; 12(11):2288-95. PubMed ID: 7964942
[TBL] [Abstract][Full Text] [Related]
17. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
Bartlett DL; Libutti SK; Figg WD; Fraker DL; Alexander HR
Surgery; 2001 Feb; 129(2):176-87. PubMed ID: 11174711
[TBL] [Abstract][Full Text] [Related]
18. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
Holster JJ; El Hassnaoui M; Franssen S; IJzermans JNM; de Jonge J; Mostert B; Polak WG; de Wilde RF; Homs MYV; Groot Koerkamp B
Ann Surg Oncol; 2022 Sep; 29(9):5528-5538. PubMed ID: 35294656
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers.
Robertson JM; Lawrence TS; Andrews JC; Walker S; Kessler ML; Ensminger WD
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(2):325-30. PubMed ID: 9069303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
